Targeting CD47 in Anaplastic Thyroid Carcinoma Enhances Tumor Phagocytosis by Macrophages and Is a Promising Therapeutic Strategy

Background: Anaplastic thyroid carcinoma (ATC) is one of the most aggressive human cancers, with a median survival of only three to six months. Standard treatment options and even targeted therapies have so far failed to improve long-term overall survival. Thus, novel treatment modalities for ATC, s...

Descripción completa

Detalles Bibliográficos
Autores principales: Schürch, Christian M., Roelli, Matthias A., Forster, Stefan, Wasmer, Marie-Hélène, Brühl, Frido, Maire, Renaud S., Di Pancrazio, Sergio, Ruepp, Marc-David, Giger, Roland, Perren, Aurel, Schmitt, Anja M., Krebs, Philippe, Charles, Roch-Philippe, Dettmer, Matthias S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mary Ann Liebert, Inc., publishers 2019
Materias:
Thyroid Cancer and Nodules
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6648226/
https://www.ncbi.nlm.nih.gov/pubmed/30938231
http://dx.doi.org/10.1089/thy.2018.0555

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6648226/
https://www.ncbi.nlm.nih.gov/pubmed/30938231
http://dx.doi.org/10.1089/thy.2018.0555

Ejemplares similares